Archives of Virology

, Volume 162, Issue 3, pp 713–720 | Cite as

Development of a fluorescence resonance energy transfer–based intracellular assay to identify novel enterovirus 71 antivirals

  • Wen-Wen Lu
  • Fang-Yen Kung
  • Po-An Deng
  • Yu-Chu Lin
  • Cheng-Wen Lin
  • Szu-Hao Kung
Original Article


Enterovirus 71 (EV71) is considered one of the most virulent pathogens in the family Picornaviridae. However, there have been no effective treatments for the severe complications caused by EV71. Development of new drugs against targets that are essential for viral replication often requires screening large collections of compounds, for which a high-throughput screening platform is needed. In this study, a drug-screening platform was developed based on a genetically engineered cell line that displays fluorescence resonance energy transfer (FRET) and shows a real-time and quantifiable impairment of FRET upon EV71 infection. A library of small molecules consisting of 1280 compounds with defined bioactivities was used for screening drugs with anti-EV71 activity; accurate, rapid, and robust results were obtained from this screening procedure. Ten drugs were identified in the primary screening, and their antiviral activities were indicated by dose-dependent elevation of FRET. Among these, AC-93253, mitoxantrone and N-bromoacetamide had not been reported as enterovirus inhibitors, and it was confirmed that they were able to suppress viral yields in a dose-dependent manner. Taken together, these studies demonstrate the feasibility of this FRET-based platform for efficient screening and identification of novel compounds with activity against EV71 infection.


Ouabain Mitoxantrone Fluorescence Resonance Energy Transfer Internal Ribosome Entry Site EV71 Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was funded by the Ministry of Education of Taiwan (a grant from Ministry of Education, Aim for the Top University Plan [Grant 104AC-D104]) and the Cheng Hsin General Hospital Foundation (Grant 102-61).

Compliance with ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

705_2016_3143_MOESM1_ESM.pdf (40 kb)
Supplementary material 1 (PDF 40 kb)


  1. 1.
    Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T (2010) Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 9:1097–1105CrossRefPubMedGoogle Scholar
  2. 2.
    Wang SM, Liu CC (2014) Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti Infect Ther 12:447–456CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778–790CrossRefPubMedGoogle Scholar
  4. 4.
    Thibaut HJ, De Palma AM, Neyts J (2012) Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83:185–192CrossRefPubMedGoogle Scholar
  5. 5.
    Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Sola M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R (2011) Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res 89:204–218CrossRefPubMedGoogle Scholar
  6. 6.
    Niepmann M (2009) Internal translation initiation of picornaviruses and hepatitis C virus. Biochim Biophys Acta 1789:529–541CrossRefPubMedGoogle Scholar
  7. 7.
    van der Linden L, Wolthers KC, van Kuppeveld FJ (2015) Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7:4529–4562CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Campagnola G, Gong P, Peersen OB (2011) High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Res 91:241–251CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R (2008) Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother 52:3385–3393CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P (2012) Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother 56:4838–4844CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Arita M, Wakita T, Shimizu H (2008) Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89:2518–2530CrossRefPubMedGoogle Scholar
  12. 12.
    Hsu YY, Liu YN, Lu WW, Kung SH (2009) Visualizing and quantifying the differential cleavages of the eukaryotic translation initiation factors eIF4GI and eIF4GII in the enterovirus-infected cell. Biotechnol Bioeng 104:1142–1152CrossRefPubMedGoogle Scholar
  13. 13.
    Piston DW, Kremers GJ (2007) Fluorescent protein FRET: the good, the bad and the ugly. Trends Biochem Sci 32:407–414CrossRefPubMedGoogle Scholar
  14. 14.
    Hsu YY, Liu YN, Wang W, Kao FJ, Kung SH (2007) In vivo dynamics of enterovirus protease revealed by fluorescence resonance emission transfer (FRET) based on a novel FRET pair. Biochem Biophys Res Commun 353:939–945CrossRefPubMedGoogle Scholar
  15. 15.
    Tsai MT, Cheng YH, Liu YN, Liao NC, Lu WW, Kung SH (2009) Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob Agents Chemother 53:748–755CrossRefPubMedGoogle Scholar
  16. 16.
    Gero D, Modis K, Nagy N, Szoleczky P, Toth ZD, Dorman G, Szabo C (2007) Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay. Int J Mol Med 20:749–761PubMedGoogle Scholar
  17. 17.
    Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73CrossRefPubMedGoogle Scholar
  18. 18.
    Lu JR, Lu WW, Lai JZ, Tsai FL, Wu SH, Lin CW, Kung SH (2013) Calcium flux and calpain-mediated activation of the apoptosis-inducing factor contribute to enterovirus 71-induced apoptosis. J Gen Virol 94:1477–1485CrossRefPubMedGoogle Scholar
  19. 19.
    Barton DJ, Flanegan JB (1997) Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J Virol 71:8482–8489PubMedPubMedCentralGoogle Scholar
  20. 20.
    Belov GA, Ehrenfeld E (2007) Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle 6:36–38CrossRefPubMedGoogle Scholar
  21. 21.
    Irurzun A, Perez L, Carrasco L (1992) Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166–175CrossRefPubMedGoogle Scholar
  22. 22.
    Kang H, Kim C, Kim DE, Song JH, Choi M, Choi K, Kang M, Lee K, Kim HS, Shin JS, Kim J, Han SB, Lee MY, Lee SU, Lee CK, Kim M, Ko HJ, van Kuppeveld FJ, Cho S (2015) Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral Res 124:1–10CrossRefPubMedGoogle Scholar
  23. 23.
    Hou HY, Lu WW, Wu KY, Lin CW, Kung SH (2016) Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J Gen Virol 97:1122–1133CrossRefPubMedGoogle Scholar
  24. 24.
    Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ (2012) High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One 7:e36594CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ramabhadran TV, Thach RE (1980) Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication. J Virol 34:293–296PubMedPubMedCentralGoogle Scholar
  26. 26.
    Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF (2012) Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog 8:e1002976CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV (2008) Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral Res 77:232–236CrossRefPubMedGoogle Scholar
  28. 28.
    Lingrel JB (2010) The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na, K-ATPase. Annu Rev Physiol 72:395–412CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Elnaggar M, Giovannetti E, Peters GJ (2012) Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des 18:2811–2829CrossRefPubMedGoogle Scholar
  30. 30.
    Piu F, Gauthier NK, Olsson R, Currier EA, Lund BW, Croston GE, Hacksell U, Brann MR (2005) Identification of novel subtype selective RAR agonists. Biochem Pharmacol 71:156–162CrossRefPubMedGoogle Scholar
  31. 31.
    Botta G, De Santis LP, Saladino R (2012) Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Curr Med Chem 19:5871–5884CrossRefPubMedGoogle Scholar
  32. 32.
    Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63:S15–S18CrossRefPubMedGoogle Scholar
  33. 33.
    Boccara G, Choby C, Frapier JM, Quignard JF, Nargeot J, Dayanithi G, Richard S (1999) Regulation of Ca2+ homeostasis by atypical Na+ currents in cultured human coronary myocytes. Circ Res 85:606–613CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  1. 1.Department of Clinical PathologyCheng Hsin General HospitalTaipeiTaiwan, R.O.C.
  2. 2.Department of Biotechnology and Laboratory Science in MedicineNational Yang-Ming UniversityTaipeiTaiwan, R.O.C.
  3. 3.Department of Medical Laboratory Science and BiotechnologyChina Medical UniversityTaichungTaiwan, R.O.C.

Personalised recommendations